Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39,987 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Feyerabend S, Saad F, Li T, Ito T, Diels J, Van Sanden S, De Porre P, Roiz J, Abogunrin S, Koufopoulou M, Fizazi K. Feyerabend S, et al. Among authors: li t. Eur J Cancer. 2018 Nov;103:78-87. doi: 10.1016/j.ejca.2018.08.010. Epub 2018 Sep 12. Eur J Cancer. 2018. PMID: 30218976 Free article.
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
Minchom A, Viteri S, Bazhenova L, Gadgeel SM, Ou SI, Trigo J, Bauml JM, Backenroth D, Bhattacharya A, Li T, Mahadevia P, Girard N. Minchom A, et al. Among authors: li t. Lung Cancer. 2022 Jun;168:74-82. doi: 10.1016/j.lungcan.2022.03.005. Epub 2022 Mar 8. Lung Cancer. 2022. PMID: 35597172 Free article.
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
Chouaid C, Bosquet L, Girard N, Kron A, Scheffler M, Griesinger F, Sebastian M, Trigo J, Viteri S, Knott C, Rodrigues B, Rahhali N, Cabrieto J, Diels J, Perualila NJ, Schioppa CA, Sermon J, Toueg R, Erdmann N, Mielke J, Nematian-Samani M, Martin-Fernandez C, Pfaira I, Li T, Mahadevia P, Wolf J. Chouaid C, et al. Among authors: li t. Adv Ther. 2023 Mar;40(3):1187-1203. doi: 10.1007/s12325-022-02408-7. Epub 2023 Jan 18. Adv Ther. 2023. PMID: 36652175 Free PMC article.
A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion-mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study.
Girard N, Park K, Lee SH, Viteri S, Schioppa CA, Diels J, Oguz M, Rodrigues BH, Rahhali N, Sermon J, Ghilotti F, Li T, Thayu M, Knoblauch RE, Mahadevia P, Cho BC. Girard N, et al. Among authors: li t. Cancer Treat Res Commun. 2024;40:100832. doi: 10.1016/j.ctarc.2024.100832. Epub 2024 Jul 9. Cancer Treat Res Commun. 2024. PMID: 39033692 Free article. Clinical Trial.
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K. Chi KN, et al. Among authors: li t. Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8. Lancet Oncol. 2018. PMID: 29326030 Clinical Trial.
39,987 results
You have reached the last available page of results. Please see the User Guide for more information.